Founded in 1995, Snibe is a global leading in-vitro diagnostic solution provider who has focused on the chemiluminescence immunoassay (CLIA) field for more than 29 years and also become the first CLIA manufacturer in China to get FDA-cleared. At present, we have provided customized diagnostic solutions to laboratories in more than 156 countries and regions. Over 30,000 units of Snibe's products have reached worldwide, including global chain labs and hospitals like Synlab, Eurofins, Cerba, Synevo, etc.

Snibe established 4 core R&D centers, including reagent, instrument, magnetic microbead, and reagent raw material to lay a solid foundation for developing the broadest range of CLIA analyzers and a relevant test menu with more than 236 parameters. Under strong technical support, we successfully launched one of the fastest CLIA analyzer in the world - MAGLUMI X8 with a throughput of 600T/H in 2018; In order to meet the demand of mega-laboratories, Snibe announced a strategic partnership with Thermofisher and Hitachi to launch the Total Laboratory Automation solution in 2019; Moreover, to help fight against COVID-19, Snibe successfully developed the 2019-nCoV (SARS-CoV-2) CLIA Kits in 2020, the first of its kind in the world to receive the CE mark.

"Creating value for human health through continuous innovation" is our mission. Snibe's striving for excellence never ends.